CSIMarket


Baudax Bio Inc   (BXRX)
Other Ticker:  
 


 

Baudax Bio Inc

BXRX's Financial Statements and Analysis



Baudax Bio Inc narrowed third quarter of 2023 net loss per share of $-0.30 compare to net loss per share of $-2.47 recorded in the same quarter a year ago and improved compare to net loss per share of $-1.51 realized in previous quarter.


third quarter of 2023
Earnings Per Share Revenues
$ -0.3 $  0 Mill
$+2.17     Unch.    



Baudax Bio Inc 's Revenue fell by 0 % in third quarter of 2023 (Sep 30 2023) year on year, to $0 million and declined by sequentially.


Baudax Bio Inc is

More on BXRX's Income Statement



Baudax Bio Inc 's in thethird quarter of 2023 recorded net loss of $-1.934 million, an improvement compare to net loss of $-29.205 million in III. Quarter a year ago.

Sequentially net loss narrowed from net loss of $-7.375 million realized in previous quarter.

More on BXRX's Growth

Baudax Bio Inc Inventories
In Sep 30 2023 company's net cash and cash equivalents decreased by $-1 million

More on BXRX's Cash flow Statement


Baudax Bio Inc does not pay out common stock dividend.

In trailing twelve-month period Baudax Bio Inc payed $ -1.68 cash per share, on a free-cash flow basis .


Tangible Book value grew to $ -2.87 per share from $ -4.79.

Company issued 3.11 million shares or 63.63 % in Sep 30 2023.


More on BXRX's Dividends

 Market Capitalization (Millions) 0
 Shares Outstanding (Millions) 8
 Total Debt (Millions $) 4
 Revenue (TTM) (Millions $) -
 Net Income (TTM) (Millions $) -7
 Cash Flow (TTM) (Millions $) -4
 Capital Exp. (TTM) (Millions $) 0
 Dividend TTM ($) 0 $
 Dividend Yield TTM (%) -
 Employees (TTM) $ -




Baudax Bio Inc does not pay out common stock dividend.

In trailing twelve-month period Baudax Bio Inc had negative $ -1.68 cash flow per share, on a free-cash flow basis .


Tangible Book value grew to $ -2.87 per share from $ -4.79.

Company issued 3.11 million shares or 63.63 % in Sep 30 2023.


More on BXRX's Balance Sheets

 Market Capitalization (Millions) 0
 Shares Outstanding (Millions) 8
 Total Debt (Millions $) 4
 Revenue (TTM) (Millions $) -
 Net Income (TTM) (Millions $) -7
 Cash Flow (TTM) (Millions $) -4
 Capital Exp. (TTM) (Millions $) 0
 Dividend TTM ($) 0 $
 Dividend Yield TTM (%) -
 Employees (TTM) $ -
   


  News about Baudax Bio Inc Earnings

Baudax Bio Inc's Revenue Shows Steady Comparison to Previous Year During July-September 2023 Period



Baudax Bio Inc, a pharmaceutical company listed on the NASDAQ, recently released its financial results for the July to September 2023 period. The company demonstrated significant improvements in its loss per share and earnings per share compared to the previous year and the previous quarter. Despite revenue remaining unchanged, Baudax Bio Inc reported a substantial decrease in its net shortfall. This article aims to outline the facts and interpret these financial results.
1. Improving Financial Performance:
For the July to September 2023 period, Baudax Bio Inc managed to decrease its loss per share from $-2.47 to $-0.30 when compared to the same quarter last year, showcasing a remarkable im...

Baudax Bio Inc shines with a series of remarkable achievements throughout Q2 2023

Baudax Bio Inc, a pharmaceutical company, recently released its financial results for the second quarter of 2023. The company reported a shortfall per share of $-1.51 compared to $-1.05 in the same period last year. Additionally, the earnings per share (EPS) fell from $4.91 in the preceding reporting period. Though these figures may seem concerning, it is essential to analyze the larger context of the company's performance.
One key point to note is that Baudax Bio Inc experienced no change in revenue, with $0.00 million reported for the second quarter of 2023. This is consistent with the revenue figures from the previous year, which also stood at $0.00 million. While flat revenue may not indicate signifi...

Baudax Bio Inc Surprises Investors with Stunning Turnaround, Reports EPS of $4.91 per Share in Q1 2023

Baudax Bio Inc, a pharmaceutical company that operates in the pain management sector, recently announced impressive financial results for the period closing March 31, 2023. The company surprised investors and analysts alike by posting earnings per share (EPS) of $4.91 per share, a stark improvement from the negative EPS of $-3.17 from the previous year, indicating a significant turnaround in their financial fortunes.
Furthermore, Baudax Bio Inc's revenues remained somewhat constant, standing at $0.00 million, mirroring the previous year's figure of $0.42 million. Although there was no significant improvement on the revenue side, it was a positive indicator that the company had managed to maintain its pos...


Date modified: 2023-11-21T23:24:05+00:00





Help

About us

Advertise

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research. 
   Copyright © 2024 CSIMarket, Inc. All rights reserved. This site uses cookies to make your browsing experince better. By using this site, you agree to the Terms of Service and Privacy Policy - UPDATED (Read about our Privacy Policy)

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com